Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness

Clinical Trials

Volumn 6, Issue 4, 2009, Pages 305-319

  Gould, Lawrence A ^a   Koglin, Joerg ^a   Bain, Raymond P ^a   Pinto, Cathy Anne ^a   Mitchel, Yale B ^a   Pasternak, Richard C ^a   Sapre, Aditi ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; NICOTINIC ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BAYES THEOREM; CAROTID ARTERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; UNCERTAINTY; CAROTID ARTERY DISEASES; DRUG EFFECTS; INTIMA; METHODOLOGY; MONTE CARLO METHOD; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH; RISK FACTOR; STATISTICAL MODEL; TUNICA MEDIA;

BAYES THEOREM; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; HUMANS; HYPOLIPIDEMIC AGENTS; MODELS, STATISTICAL; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH; RESEARCH DESIGN; RISK FACTORS; SAMPLE SIZE; TUNICA INTIMA; TUNICA MEDIA;

EID: 70449653301     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774509339977     Document Type: Article

References (42)

1. Lorenz MW, Markus HS, Bots ML et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 2007; 115: 459-67.
2. O'Leary DH, Polak JF Intima-media thickness: A tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90: 18L-21L.
3. Chambless LE, Heiss G., Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94.
4. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
5. Kastelein JJ, de Groot E., Sankatsing R. Atherosclerosis measured by B-mode ultrasonography: Effect of statin therapy on disease progression. Am J Med 2004; 116: 31S-6S.
6. Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 2008; 29: 849-58.
7. Kastelein JJ, Akdim F., Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
8. Bots ML, Visseren FL, Evans GW et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet 2007; 370: 153-60.
9. Kastelein JJ, van Leuven SI, Burgess L. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-30.
10. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-17.
11. Gould AL Timing of futility analyses for "proof of concept" trials. Stat Med 2005; 24: 1815-35.
12. Smilde TJ, van Wissen S., Wollersheim H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
13. Crouse JR III, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 2007; 297: 1344-53.
14. Johnson NL, Welch BL Applications of the non-central t-distribution. Biometrika 1940; 31: 362-89.
15. Verrill S. Confidence Bounds for Normal and Lognormal Distribution Coefficients of Variation. FPL-RP-609. Department of Agriculture, Forest Service, Forest Products Laboratory, Madison, WI, 2003, pp. 1-13.
16. Whitehead A., Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-77.
17. Senn S. Trying to be precise about vagueness. Stat Med 2007; 26: 1417-1430.
18. Lambert PC, Sutton AJ, Burton PR et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005; 24: 2401-28.
19. Hedges LV Meta-analysis. J Edu Stat 1992; 17: 279-96.
20. Thomas A., O'Hara B., Ligges U., Sullenberger LE Making BUGS open. R News 2006; 6: 12-21.
21. Hodis HN, Mack WJ, LaBree L. et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann Intern Med 1996; 124: 548-56.
22. ]MacMahon S., Sharpe N., Gamble G. et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784-90.
23. Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
24. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-59.
25. de Groot E., Jukema JW, Montauban van Swijndregt AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll.Cardiol 1998; 31: 1561-67.
26. Probstfield JL, Margitic SE, Byington RP et al. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995; 76: 47C-53C.
27. de Groot E., van Leuven SI, Duivenvoorden R. et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 2008; 5: 280-88.
28. Bots ML, Evans GW, Riley WA, Grobbee DE Carotid intima-media thickness measurements in intervention studies: Design options, progression rates, and sample size considerations: A point of view. Stroke 2003; 34: 2985-94.
29. Cheng KS, Mikhailidis DP, Hamilton G., Seifalian AM A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528-38.
30. Wendelhag I., Wiklund O., Wikstrand J. On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. Arterioscler.Thromb.Vasc Biol 1996; 16: 843-50.
31. Wittekoek ME, de Groot E., Prins MH et al. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146: 271-79.
32. van Wissen S., Smilde TJ, Trip MD et al. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95: 264-66.
33. Forkman J., Verrill S. The distribution of McKay's approximation for the coefficient of variation. Stat Prob Lett 2008;78: 10-14.
34. McKay AT Distribution of the coefficient of variation and the extended "t" distribution. J Royal Stat Soc 1932; 95: 695-98.
35. Ng CK Performance of three methods of interval estimation of the coefficient of variation. Inter Stat: Stat Internet 2005; 9: 1-8.
36. Lunn DJ, Thomas A., Best N., Spiegelhalter DJ WinBUGS - a Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000; 10: 325-37.
37. Mack WJ, LaBree L., Liu C. et al. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis 2000; 150: 371-79.
38. Salonen R., Nyyssonen K., Porkkala E. et al. Kuopio atherosclerosis prevention study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
39. Mercuri M., Bond MG, Sirtori CR et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627-34.
40. Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641-48.
41. Hedblad B., Wikstrand J., Janzon L. et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-26.
42. Nanayakkara PW, van Guldener C., ter Wee PM et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007; 167: 1262-70.